Genetic Predisposition and Pharmacological Effects Shape the Divergent Effects of Type 2 Diabetes on Atherosclerosis
Genomics, Proteomics & Bioinformatics · 08.08.2026
DOI: 10.1093/gpbjnl/qzag079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genomics, Proteomics & Bioinformatics, online erschienen am 08.08.2026. Verfasst von Shufen Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou 511453, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2D) increases the risk of atherosclerotic diseases, including coronary artery disease (CAD), but decreases that for abdominal aortic aneurysm (AAA), forming an intriguing diabetes-atherosclerosis paradox. We investigate how genetic underpinnings and drug effects shape these complex relationships. A robust positive correlation between T2D and CAD is found throughout the genome, whereas the weak genetic correlation between T2D and AAA is counter-balanced by two-thirds positive and one-third negative correlations. Through single nucleotide variant colocalization, gene annotation, pathway enrichment, and cell type associations, we discover that these positive correlations entail immune responses, whereas the negative correlation is characterized by beta-cell dysfunction and lipid metabolism. Furthermore, the effects of 98 canonical cardiovascular and metabolic drugs are elucidated by pathway pairing and drug-target Mendelian Randomization, revealing that the widely prescribed metformin and glitazones are also protective against atherosclerosis, whereas statins raise the T2D risk. Through screening the plasma proteome against 660 anti-inflammatory drugs, we identify 14 targets and 8 drugs for anti-inflammatory treatments of T2D and atherosclerosis. Our study discovers that both disease-disease and drug-disease interplay contribute to the complex relationships between diabetes and atherosclerosis. Importantly, immune responses synergize with diabetes and atherosclerotic diseases, suggesting anti-inflammatory therapies as a unified treatment strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou 511453, China.
- School of Life Sciences, Fudan University, Shanghai 200438, China.
- Center for Cell and Gene Therapy, Greater Bay Area Institute of Precision Medicine (Guangzhou), Guangzhou 511466, China.
- Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, CA 94305, USA.
- Stanford Cardiovascular Institute, Stanford University, California, CA 94305, USA.
ORCID-Profile: Shufen Zheng, Yonglin Wu, Aijie Li, Zhuoyi Wu, Zhen Liu, Huawei Wang, Xiaoyan Jia, Philip S Tsao, Cuiping Pan
Zitieren
APA
Zheng, S., Wu, Y., Li, A., Wu, Z., Liu, Z., Wang, H., Jia, X., Tsao, P. S., & Pan, C. (2026). Genetic Predisposition and Pharmacological Effects Shape the Divergent Effects of Type 2 Diabetes on Atherosclerosis. Genomics, Proteomics & Bioinformatics. https://doi.org/10.1093/gpbjnl/qzag079
Vancouver
Zheng S, Wu Y, Li A, Wu Z, Liu Z, Wang H, et al. Genetic Predisposition and Pharmacological Effects Shape the Divergent Effects of Type 2 Diabetes on Atherosclerosis. Genomics, Proteomics & Bioinformatics. 2026. doi:10.1093/gpbjnl/qzag079
BibTeX
@article{Zheng2026,
author = {Zheng, Shufen and Wu, Yonglin and Li, Aijie and Wu, Zhuoyi and Liu, Zhen and Wang, Huawei and Jia, Xiaoyan and Tsao, Philip S and Pan, Cuiping},
title = {Genetic Predisposition and Pharmacological Effects Shape the Divergent Effects of Type 2 Diabetes on Atherosclerosis},
journal = {Genomics, Proteomics & Bioinformatics},
year = {2026},
doi = {10.1093/gpbjnl/qzag079}
}
EUVIMED